Reported Treatments and the HSCT Evaluation

Managing ITCH deficiency is a complex balancing act. Because the immune system lacks proper regulation, doctors must use powerful medications to manually turn down the volume of the immune response ^[1]. While these treatments can control immediate flares, they rarely offer a permanent solution. For many families, the conversation eventually shifts from managing symptoms to evaluating a potential disease-modifying cure through a stem cell transplant ^[2][3]. There is no well-established, standardized ITCH-specific regimen.

Reported and Supportive Treatments

The first line of defense generally involves medical management, using drugs that suppress or modify the immune system. The goal is to stop the body from attacking its own organs while still leaving enough immune function to fight off dangerous infections ^[4].

• Corticosteroids (e.g., Prednisone): These are often used because they work quickly to dampen inflammation. However, children with ITCH deficiency often become steroid-dependent, meaning their symptoms return as soon as the dose is lowered ^[2]. Long-term use of high-dose steroids can lead to “treatment-related morbidity,” including stunted growth, weakened bones, and a higher risk of severe infections ^[2][5].
• Biologic Therapies and Immunosuppressants: Doctors may try a variety of specialized off-label medications, such as TNF inhibitors or JAK inhibitors, to target specific inflammatory pathways. While these can be helpful in other immune disorders, evidence in ITCH deficiency is limited. In reported cases, even with multiple biologics and immunosuppressants, many children continue to experience poor disease control and ongoing organ damage ^[2].
• The Risk of “Multisystem Morbidity”: Even with intensive medication, new autoimmune problems can still emerge. For example, one child who received a liver transplant and standard immunosuppression still went on to develop type 1 diabetes and thyroiditis while on treatment ^[5]. Furthermore, the combination of the disease itself and the drugs used to treat it can leave the body vulnerable to life-threatening viral, bacterial, and fungal infections ^[5].

A Path Toward Disease Modification: Hematopoietic Stem Cell Transplantation (HSCT)

Because the primary “error” in ITCH deficiency is located within the immune cells themselves, replacing those cells can potentially control the disease. This is done through an allogeneic hematopoietic stem cell transplant (HSCT), often referred to as a bone marrow transplant ^[3].

In an HSCT, the child’s existing immune system is suppressed using chemotherapy (a process called conditioning) and replaced with healthy stem cells from a donor ^[3]. These new cells grow into a functional immune system that includes the functioning ITCH protein ^[6].

Reported Outcomes in ITCH Deficiency

Because the condition is so rare, only two human cases of HSCT for ITCH deficiency have been detailed in medical literature as of recent reviews:

1. A Young Child Case: A young child with severe gut, skin, and joint issues underwent HSCT. The report noted “excellent immune reconstitution,” leading to the resolution of many of the child’s autoimmune symptoms ^[3].
2. An Adult Case: A 20-year-old woman who had suffered for years with progressive muscle weakness and lung disease underwent the procedure. After the transplant, she achieved remission of autoimmune activity and was able to stop immunosuppressive medications ^[2]. Her chronic lung disease improved so much that she no longer needed a ventilator to breathe ^[2].

Importantly, because the ITCH variant is germline (present in all cells of the body), HSCT does not replace the altered cells in non-blood tissues. It also does not necessarily reverse established permanent structural damage that has already occurred, such as severe lung scarring (bronchiectasis) or liver cirrhosis.

Weighing the Risks

The decision to pursue a transplant is never easy. It involves comparing two different types of risk:

• The Risks of Chronic Disease: This includes the cumulative damage to the lungs, liver, and gut from ongoing inflammation, as well as the long-term side effects of steroids and other immunosuppressants ^[2].
• The Risks of HSCT: A transplant is a major medical procedure. It carries severe risks including transplant-related mortality, graft failure (the donor cells fail to grow), severe infection during the recovery period, and Graft-versus-Host Disease (GvHD), where the new immune system attacks the child’s body ^[7][8]. Long-term toxicity can include infertility, premature ovarian failure, and organ injury.

Expert centers often recommend an HSCT consultation when the disease is progressive, organ-threatening, or poorly controlled by standard medications ^[2][3]. Because every child is different, it is vital to consult with a specialized center that has experience in treating Inborn Errors of Immunity (IEI) to discuss whether your child is a candidate.